Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-11-14
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 60
- Registration Number
- NCT00140465
- Locations
- 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 457
- Registration Number
- NCT00130039
- Locations
- 🇰🇷
Inje University Ilsan Paik Hospital, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷Dongguk University International Hospital, Goyang, Kyoungki-do, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Kyunggi, Korea, Republic of
Which Therapy for Acute Heart Attacks? (The WEST Study)
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 300
- Registration Number
- NCT00121446
- Locations
- 🇨🇦
Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Alberta, Canada
🇨🇦Misericordia Hospital, Edmonton, Alberta, Canada
Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)
- Conditions
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2008-04-08
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 500
- Registration Number
- NCT00109382
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦Universtiy of Alberta Walter MacKenzie Health Sciences Centre, Edmonton, Alberta, Canada
🇨🇦London Health Sciences Centre - University Hospital, London, Ontario, Canada
A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension
- Conditions
- First Posted Date
- 2005-03-10
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Kawut, Steven, MD
- Target Recruit Count
- 20
- Registration Number
- NCT00105209
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Columbia University College of Physicians and Surgeons, New York, New York, United States
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13619
- Registration Number
- NCT00097591
- Locations
- 🇺🇸
For more information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), Global Quintiles Study Line (1-866-615-4672) or speak with your physician, Indianapolis, Indiana, United States
Secondary Prevention of Small Subcortical Strokes Trial
- Conditions
- Interventions
- First Posted Date
- 2003-04-24
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 3020
- Registration Number
- NCT00059306
- Locations
- 🇺🇸
Ohio State University, Division of Stroke, Columbus, Ohio, United States
🇺🇸Marshfield Clinic, Department of Neurology, Marshfield, Wisconsin, United States
🇺🇸Metrohealth Medical Center, Cleveland, Ohio, United States
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Interventions
- First Posted Date
- 2003-04-23
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 905
- Registration Number
- NCT00059215
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Boston, Massachusetts, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, British Columbia, Canada
The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
- Conditions
- First Posted Date
- 2000-02-14
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00004564
- Locations
- 🇺🇸
1G323 University Hospital, Box 0048 1500 E Medical Center Drive, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.